Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Heidelberg
With
German Cancer Research Center
Heidelberg University
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven clinical stage I to IIA pulmonary adenocarcinoma
Lung tumor is felt to be curatively resectable by the treating physicians
Sufficient pulmonary function for lobectomy according to current guidelines
The patient is free of distant metastases as confirmed by contrast-enhanced chest and upper abdomen CT-scan and by contrast-enhanced CT or MRI of the brain
Age over 50years at the time of consent due to federal radiation protection law
In female patients of childbearing potential there must be a negative pregnancy test
Eastern Cooperative Oncology Group performance status of 0,1, 2 or 3 at the time of randomization
Patients who the investigator believes can and will comply with the requirements of this protocol
Written informed consent according to good clinical practise and national/regional regulations
The patient has been diagnosed with a potential immune mediated disease
Elevated blood leukocyte count or erythrocyte sedimentation rate
Pregnancy
The patient has received any cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy or chemotherapy
The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years
The patient needs chronic long term oxygen therapy
The patient has undergone splenectomy
The patient is known to be HIV positive
The patient has an uncontrolled bleeding disorder
Clareo Health | Immune Boost In Non-Small Cell Lung Cancer
